Norethisterone Acetate
PreclinicalSmall molecule
Norethisterone Acetate is one of 15 small molecule programs targeting Uterine leiomyoma. It is currently in Preclinical.
3
Indications
7
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Menorrhagia
#DrugCompanyPhaseTrials
1Cyklokapron
JJ Molner
Approved
Danocrine
SanofiApproved
Cytotec
PfizerApproved
Jadelle
IItalian Network for Tumor Biotherapy Foundation
Approved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Estrasorb
Novo NordiskPreclinical
Nuvaring
UUniversity of Washington
Preclinical
Dienogest
BayerPreclinical
Hormonal Treatment
BayerPreclinical
Norethisterone Acetate
MMansoura University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chemotherapy1 trial
Atypical Endometrial Hyperplasia1 trial
Menorrhagia1 trial
2 more indications
Ovarian cyst1 trial
A Trial of Norethisterone Acetate and Expectant Management in Treatment of Simple Ovarian Cysts
Unknown status·—·Phase 4·NCT05293574·66 enrolled
Endometrial1 trial
Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature .
Unknown status·—·Phase 3·NCT04290013·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Norethisterone Acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMansoura University